Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact de l'ICCAN sur l'achèvement du traitement du cancer et la qualité de vie

16 septembre 2026 mis à jour par: Memorial Sloan Kettering Cancer Center

Un essai contrôlé randomisé de l'impact de l'ICCAN sur l'achèvement du traitement du cancer et la qualité de vie

The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Estimé)

347

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Francesca Gany, MD, MS
  • Numéro de téléphone: 646-888-8054

Sauvegarde des contacts de l'étude

  • Nom: Jennifer Leng, MD, MPH
  • Numéro de téléphone: 646-888-4243

Lieux d'étude

    • New Jersey
      • Basking Ridge, New Jersey, États-Unis, 07920
        • Recrutement
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • Contact:
          • Francesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
      • Middletown, New Jersey, États-Unis, 07748
        • Recrutement
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Contact:
          • Fransecsa Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
      • Montvale, New Jersey, États-Unis, 07645
        • Recrutement
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Contact:
          • Francesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
    • New York
      • Brooklyn, New York, États-Unis, 11220
        • Actif, ne recrute pas
        • Lutheran Medical Center
      • Commack, New York, États-Unis, 11725
        • Recrutement
        • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
        • Contact:
          • Francesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
      • Harrison, New York, États-Unis, 10604
        • Recrutement
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • Contact:
          • Francesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
        • Contact:
          • Francesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
        • Contact:
          • Jennifer Leng, MD, MPH
          • Numéro de téléphone: 646-888-4243
        • Chercheur principal:
          • Francesca Gany, MD, MS
      • New York, New York, États-Unis, 10035
        • Recrutement
        • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
        • Contact:
          • Francesca Gany, MD
          • Numéro de téléphone: 646-888-8054
      • New York, New York, États-Unis, 10031
        • Recrutement
        • City College of New York (Data Collection AND Data Analysis)
        • Contact:
      • Rockville Centre, New York, États-Unis, 11553
        • Recrutement
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Contact:
          • Franscesca Gany, MD, MS
          • Numéro de téléphone: 646-888-8054
      • The Bronx, New York, États-Unis
        • Actif, ne recrute pas
        • Lincoln Hospital and Mental Health Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Eligible cancer patients will be recruited in person by multilingual ICCAN Clinical Research Coordinators for participation in the study at Ralph Lauren Center for Cancer Care and Prevention (RLCCP), Lincoln Hospital (LH) and Lutheran Medical Center (LMC). In the event that MSK staff is not present when an eligible patient is identified. Refinement and Pilot RCT participants will be recruited through MSK Manhattan and OneMSK regional sites's.

La description

Participant Inclusion Criteria:

Patient is eligible if he/she is

  • fluent in English, Spanish, or Mandarin
  • between the ages of 21-80 years old
  • cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
  • scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
  • planning on remaining in the area for at least 1 year

Clinician is eligible if he/she:

  • Has an MD or DO degree
  • Is the treating physician providing care to a patient enrolled to the study

ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:

  • Is 18 - 85 years of age
  • Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
  • Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
  • Is treated in the NY metropolitan area
  • Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income < 200% of federal poverty level)
  • Has English or Spanish proficiency
  • Agrees to be audio-recorded

ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:

  • Is 18 - 85 years of age
  • Has stage II-III TNBC
  • Treated at MSK Manhattan or OneMSK regional sites
  • Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income < 200% of federal poverty level)
  • Has English or Spanish proficiency
  • Agrees to be audio-recorded

ICCAN-IO process evaluation study team participants only:

  • Staff member who serves as an Access Facilitator
  • Agrees to be audio-recorded

CCAN-GBM

  • Over the age of 18 (per EMR)
  • Diagnosed with Glioblastoma (per EMR)
  • Has not yet started radiation and concurrent temozolomide treatment (per EMR)
  • Has a primary neuro-oncologist at MSK (per EMR)
  • Will be undergoing radiation at MSK (per EMR)
  • Treatment plan consists of a 6-week or 3-week (hypofractionated) course of radiation and chemotherapy (per EMR)
  • Participant or caregiver is fluent in English or Spanish
  • Planning on remaining in the tri-state area during the 6 weeks or 3 weeks of radiation and chemotherapy (per self-report)
  • Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance (per EMR or self-report), demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit), and/or requests help with SDOH resources or navigation

Participant Exclusion Criteria:

Patient is ineligible if he/she is:

  • Diagnosed with Stage IV disease
  • Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
  • Has another family member already enrolled in ICCAN (as determined by patient report)

ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:

  • Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
  • Participants or family members who are participating in MSK IHCD studies related to social determinants of health

ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:

  • Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
  • Participants or family members who are participating in MSK IHCD studies related to social determinants of health at the PI's discretion

ICCAN-GBM

  • No recurrences - must be newly diagnosed glioblastoma (per EMR)
  • Patients undergoing different treatment regimens from the 15 fraction/3 week or 30 fraction/6 week course of radiation (i.e. patients undergoing 10 fractions of palliative radiation due to poor functional status) (per EMR)
  • Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms that require individual treatment) (per EMR or self-report)
  • Severe cognitive impairment or fluent aphasia as not to understand the assessment measures, interview, or informed consent, without a health care proxy or caregiver that can assist as indicated by clinician or per judgement of study staff. Completion of assessments with the help of caregivers is acceptable. (per EMR or self-report)
  • Has another family member or household member already enrolled in ICCAN (per self-report)
  • Already participated in or already completed the ICCAN program (per self-report)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Phase I: Refinement

10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Phase II, Arm 1: Usual and Customary Care (U&C)

Participants in this group will receive the same referrals on social and economic resources as ICCAN group.

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed.

Phase II, Arm 2: ICCAN-IO

Arm 2 will consist of everything in Arm 1

Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.

Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Treatment completion/adherence
Délai: 1 year

The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

1 year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Quality of life
Délai: 1 year

depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes

1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 novembre 2012

Achèvement primaire (Estimé)

1 novembre 2027

Achèvement de l'étude (Estimé)

1 novembre 2027

Dates d'inscription aux études

Première soumission

3 décembre 2012

Première soumission répondant aux critères de contrôle qualité

3 décembre 2012

Première publication (Estimé)

5 décembre 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 12-223

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner